Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
pathogenic b t cell axis driven by baff induces endothelial apoptosis in sle pah
Original title: “Pathogenic B-T Cell Axis Driven by BAFF Induces Endothelial Apoptosis in SLE-PAH.”
pulmonary arterial hypertension with signs of venous capillary involvement in connective tissue diseases paradigms and paradoxes
Original title: “Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes.”
exploratory assessment of catestatin and thrombospondin 1 as potential biomarkers of disease severity and treatment response in pulmonary arterial hypertension
Original title: “Exploratory assessment of catestatin and thrombospondin-1 as potential biomarkers of disease severity and treatment response in pulmonary arterial hypertension.”
global disparities in access to randomized controlled trials for pulmonary arterial hypertension
Original title: “Global disparities in access to randomized controlled trials for pulmonary arterial hypertension.”
early detection treatment initiation and long term health outcomes in patients with connective tissue disease associated pulmonary arterial hypertension a systematic literature review and expert consensus
Original title: “Early detection, treatment initiation, and long-term health outcomes in patients with connective tissue disease-associated pulmonary arterial hypertension: A systematic literature review and expert consensus.”
selexipag in systemic sclerosis associated pulmonary arterial hypertension long term real world data from a multicentre italian cohort
Original title: “Selexipag in systemic sclerosis-associated pulmonary arterial hypertension: long-term real-world data from a multicentre Italian cohort.”
european respiratory society clinical practice guidelines update for the treatment of pulmonary arterial hypertension
Original title: “European Respiratory Society clinical practice guidelines update for the treatment of pulmonary arterial hypertension.”
delays in the diagnosis and management of pulmonary arterial hypertension a simulated patient cases study across four european countries
Original title: “Delays in the diagnosis and management of pulmonary arterial hypertension: a simulated patient cases study across four European countries.”
Clinical worsening was a composite of death, hospitalization for worsening disease, and other progression measures. The components are not equivalent. Were there downsides? Yes. The Lancet reported more treatment discontinuations related to adverse events on ralinepag than on placebo. Who funded the trial? United Therapeutics, which developed the drug. The trial was randomized, double-blind, and placebo-controlled. What is PAH? A rare ... Clinical worsening was a composite of death, hospitalization for worsening disease, and other progression measures. The components are not equivalent. Were there downsides? Yes. The Lancet reported more treatment discontinuations related to adverse events on ralinepag than on placebo. Who funded the trial? United Therapeutics, which developed the drug. The trial was randomized, double-blind, and placebo-controlled. What is PAH? A rare progressive disease in which lung arteries narrow and stiffen, raising pressure and straining the right side of the heart. Published Lancet results show ralinepag reduced clinical worsening in PAH by 55%. The drug is still investigational and not FDA-approved. Treatment has improved substantially over three decades, and the paper is clear that long-term survival remains poor. The trial population reflects modern practice rather than untreated disease. Eighty percent of participants were already on two background therapies, and 70% were in the milder of the two functional classes that dominate PAH trials. That does not invalidate a randomized, double blind, placebo-controlled trial published in a major journal, and the design is the strongest available. It does mean the framing in company materials, which describes the results as exceptional and as potentially redefining PAH treatment, is promotional language rather than a scientific characterization. Context helps explain why an 18-point difference matters here. Pulmonary arterial hypertension is a rare disease in which the arteries carrying blood from the heart to the lungs narrow and stiffen.
Original title: “Lancet Results Show Ralinepag Cut Clinical Worsening by 55 Percent in Pulmonary Arterial Hypertension”
clinical practice of pulmonary arterial hypertension pah and potential barriers to intensive treatment among pah specialized and non pah specialized centers in japan
Original title: “Clinical Practice of Pulmonary Arterial Hypertension (PAH) and Potential Barriers to Intensive Treatment Among PAH-Specialized and Non-PAH-Specialized Centers in Japan.”
haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension
Original title: “Haemodynamic partial remission as a prognostic target in pulmonary arterial hypertension.”
misdiagnosed as idiopathic pah methylmalonic acidemia as a reversible cause of pediatric pulmonary hypertension
Original title: “Misdiagnosed as Idiopathic PAH: Methylmalonic Acidemia as a Reversible Cause of Pediatric Pulmonary Hypertension.”
long term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension the fonce htap randomized controlled trial
Original title: “Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the FONCE-HTAP randomized controlled trial.”
Insmed’s inhalable candidate showed “impressive” long-term efficacy in pulmonary arterial hypertension, according to analysts at Guggenheim Partners, with functional and biomarker improvements through one year of follow-up.
Original title: “Insmed moves closer to $6B opportunity as PAH drug shows long-term durability”
rituximab as a steroid sparing therapy in pediatric idiopathic pulmonary hemosiderosis a case report
Original title: “Rituximab as a Steroid-Sparing Therapy in Pediatric Idiopathic Pulmonary Hemosiderosis: A Case Report.”
challenging combination of a high cardiac output and pulmonary arterial hypertension
Original title: “The challenging combination of a high cardiac output and pulmonary arterial hypertension.”
extended follow up of cd19 car t cell therapy in connective tissue disease associated pulmonary arterial hypertension
Original title: “Extended follow-up of CD19 CAR T-cell therapy in connective tissue disease-associated pulmonary arterial hypertension.”
three dimensional micro ct analysis of vascular remodeling and vascular pruning in pulmonary arterial hypertension
Original title: “Three-dimensional micro-CT analysis of vascular remodeling and vascular pruning in pulmonary arterial hypertension.”
sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension
Original title: “Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.”
variation in snx29 and acute vasodilator response in pulmonary arterial hypertension
Original title: “Variation in SNX29 and Acute Vasodilator Response in Pulmonary Arterial Hypertension.”